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Background: Recently, the Kidney Disease: Improving Global Outcomes (KDIGO) group recommended that patients
with chronic kidney disease (CKD) be assigned according to stage and composite relative risk on the basis of
glomerular filtration rate (GFR) and albuminuria criteria. The aim of this post-hoc analysis was to investigate the
effects of add-on therapy with calcium channel blockers (CCBs) on changes in the composite ranking of relative risk
according to KDIGO guidelines. Benidipine, an L- and T-type CCB, and amlodipine, an L-type CCB to angiotensin II
receptor blocker (ARB), were examined.
Methods: Patients with blood pressure (BP) > 130/80 mmHg, an estimated GFR (eGFR) of 30–90 mL/min/1.73 m2,
and albuminuria > 30 mg/gCr, despite treatment with the maximum recommended dose of ARB, were randomly
assigned to two groups. Each group received one of two treatments: 2 mg benidipine daily, increased to 8 mg
daily (n = 52), or 2.5 mg amlodipine daily, increased to 10 mg daily (n = 52).
Results: After 6 months of treatment, a significant and comparable reduction in systolic and diastolic BP was
observed in both groups. The eGFR was significantly decreased in the amlodipine group, but there was no
significant change in the benidipine group. The decrease in albuminuria in the benidipine group was significantly
lower than in the amlodipine group. The composite ranking of relative risk according to the new KDIGO guidelines
was significantly improved in the benidipine group; however, no significant change was noted in the amlodipine
group. Moreover, significantly fewer cases in the benidipine group than the amlodipine group showed a reduced
risk category score.
Conclusion: The present post-hoc analysis showed that compared to amlodipine benidipine results in a greater
reduction in albuminuria accompanied by an improved composite ranking of relative risk according to the KDIGO
CKD severity classification.
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Chronic kidney disease (CKD) progressively increases
the risk of cardiovascular disease and end-stage renal
disease (ESRD) in line with its severity [1]. In 2002, the
Kidney Disease Outcomes Quality Initiative(KDOQI)
organization published a guideline providing diagnosis
and classification of CKD into five stages according to
severity using the glomerular filtration rate (GFR) as the
main criterion [2]. Recent studies have shown that indi-
viduals with a GFR ≤45 ml/min/1.73 m2are atincreased
risk compared with those with a higher GFR [1,3-5]. The
presence of proteinuria also increases cardio-renal
events significantly [1]. As a result, in 2009, the Kidney
Disease: Improving Global Outcomes (KDIGO) group
recommended that individuals be classified according to
proteinuria stage as well as GFR stage [1]. The diagnostic
criteria for CKD remained unchanged, but the new
KDIGO guideline divided stage 3 (30 < GFR < 60 ml/min/
1.73 m2) into the following 2 substages: 3a (GFR, 45 to <
60) and 3b (GFR, 30 to < 45). In addition, clinicians and re-
searchers were advised to categorize patients using a “heat
map” generated by the composite ranking of relative risk.
Renin-angiotensin system blockade with angiotensin-
converting enzyme inhibitors and angiotensin II type-
1 receptor blockers (ARBs) are respectively considered
the most effective pharmacological approaches for
renoprotection, reducing proteinuria more effectively
than other antihypertensive drugs [6,7]. Current guidelines
recommend blood pressure (BP) levels <130/80 mmHg in
patients with CKD [8]. However, this reduction is difficult
to achieve in CKD, and a combination of two or more
antihypertensive agents is needed in more than 60% of
patients [9]. In line with recent molecular biological stud-
ies, Ca channels are now classified into five subtypes: L, T,
N, P/Q, and R, according to their location and function
[10,11], with three types of Ca channel blocker (CCB): L-,
T-, and N-types, currently in clinical use. Both L- and T-
type Ca channels are present in afferent arterioles,
whereas only T-type channels are present in efferent arte-
rioles. Benidipine has been shown to block both L- and
T-type channels, causing dilatation of both efferent and
afferent arterioles [12], and is therefore expected to be
more advantageous than amlodipine, an L-type CCB, in
progressing renal dysfunction and decreasing albumin-
uria in patients with CKD [13-15].
We previously reported the renoprotective effects of
benidipine compared with amlodipine in patients with
CKD [13]. The main finding showed that compared
to amlodipine benidipine enhanced the maximum
recommended dose of ARBs (80 mg telmisartan daily
and 40 mg olmesartan daily, respectively) while redu-
cing albuminuria and plasma aldosterone levels over a
6-month study period, independent of its BP-lowering
effect. The aim of this post-hoc analysis was toinvestigate the effects of benidipine and amlodipine
on changes in the composite ranking of relative risk
according to the new KDIGO guidelines.
Methods
We previously conducted a 6-month, single-center, pro-
spective, randomized, open-label clinical trial [13],
designed to compare the effects of benidipine and
amlodipine on blood pressure (BP), estimated glomeru-
lar filtration rate (eGFR), and urinary albumin excretion
ratio in hypertensive and albuminuric patients with CKD
already receiving the maximum recommended dose of
ARBs. In the present study, conducted between June
2009 and May 2010, post-hoc analysis was performed to
compare the effects of benidipine and amlodipine on
changes in the composite ranking of relative risk in the
same population according to the 2009 KDIGO guide-
lines. All study participants provided written informed
consent, and the trial protocol was approved by the
Research Review Board of Nerima Hikarigaoka Hospital,
Nihon University School of Medicine and conducted in
accordance with the Declaration of Helsinki. This study
was not supported by any grants. Subjects were followed
for 6 months.
Inclusion criteria were (1) hypertension (systolic/dia-
stolic BP ≥ 130/80 mmHg measured in the sitting position
on at least two separate clinic visits), (2) stage 2–3 CKD
(eGFR 30–90 mL/min/1.73 m2) with albuminuria (urinary
albumin/creatinine (Cr) ratio ≥ 30 mg/g · Cr; average of
two consecutive measurements taken during a 4-week
period before treatment), and (3) treatment with the max-
imum recommended ARB dose (80 mg telmisartan daily
or 40 mg olmesartan daily) for at least 8 weeks prior to
the study.
Exclusion criteria were (1) age <20 years and >80 years;
(2) hypertensive emergency; (3) history of severe heart
failure, angina, myocardial infarction, or stroke within
6 months prior to the start of the trial; (4) previous treat-
ment with steroids or immunosuppressants; (5) renovas-
cular hypertension, as determined by renal Doppler
ultrasonography before enrollment in the study, or endo-
crine hypertension; and (6) severe diabetes mellitus,
resulting in hospitalization because of extremely high
plasma glucose, or with complications such as diabetic
ketoacidosis.
Subjects were randomly assigned to two groups prior
to the start of the study. An independent investigator
with no previous knowledge of the subjects before com-
mencement of the trial monitored randomization of the
order of entry of the subjects. Dynamic balancing
randomization was carried out on the basis of age, gender,
serum Cr (sCr) levels and the urinary albumin/Cr ratio
measured at the time of registration, and the presence or
absence of diabetic nephropathy. Thus, we ensured that
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characteristics of each group. The details of the assign-
ment were then given to four independent investigators.
Patients then received one of the following two treatment
regimens: 2 mg benidipine daily, increased to a daily dose
of 8 mg (benidipine group), or 2.5 mg amlodipine daily,
increased to a daily dose of 10 mg (amlodipine group).
BP was measured at the outpatient clinic at fixed
times after administration of medication according to the
Japanese Society of Hypertension 2009 guidelines [8]. Mea-
surements were performed in duplicate ever month using
a sphygmomanometer (Nippon Colin, Tokyo, Japan) with
the patient in a sitting position after a 5-min rest. Patients,
particularly those with dietary restrictions, were given guid-
ance on how to maintain their diet. Doses of ARBs and
ACE inhibitors were not altered during the study period.
The target BP level was <130/80 mmHg. During the
study period, patients were administered a combination
drug therapy that included other conventional antihyper-
tensive agents administered at baseline. Withdrawal of
treatment was considered in patients who developed an
allergy/intolerance to benidipine or amlodipine during
the study period, experienced a hypertensive emergency,
or developed any other condition or received another
therapy that, in the opinion of the investigators, might
pose a risk or confound the results of the study. Further-
more, patients administered additional antihypertensive
medication (other than ARBs or CCBs) to achieve the
target BP, when benidipine or amlodipine failed to do so,
were excluded.
All parameters used to monitor the effects of the drugs

























Figure 1 New CKD classification of relative risk according toGFR andperiod. Serum samples were assayed for Cr in a central la-
boratory (Central Laboratory; SRL Co, Tokyo, Japan) by
means of the enzymatic Cr assay method using a Japan
electron Cr auto-analyzer, model JCA-BM8060 (JEOL
Ltd., Tokyo, Japan) and enzyme solution (Preauto-S CRE-
L; Sekisui Medical Co., Ltd., Tokyo, Japan). The sCr values
obtained in the central laboratory were compared with the
standard reference material (SRM914a, The National Insti-
tute of Standards and Technology, Gaithersburg, USA) by
using a calibration panel of 50 samples. To assess urinary
albumin excretion, we measured urinary concentrations of
albumin and Cr (albumin/Cr ratio) in an early-morning
spot urine sample. Urinary albumin was measured using
the immunoturbidimetric assay. Treatment compliance
and safety variables were monitored at each visit to our
hospital. Glomerular filtration rate was estimated using
the modified final recommendation equation for Japanese
patients of the Japanese Society of Nephrology-CKD
Initiatives (JSN-CKDI), since eGFR values obtained by
this method are more accurate for Japanese patients
with CKD [16]. The following formula was used: eGFR
(mL/min/1.73 m2) = 194 × sCr–1.094 × age–0.287 (× 0.739 for
women).
The composite ranking of relative risk by GFR and
albuminuria levels was calculated according to the 2009
KDIGO recommendations using the following equations:
Risk Category No CKD G1A1, G2A1; Moderate risk
G1A2, G2A2, G3aA1; High risk G1A3, G2A3, G3aA2,
G3bA1; Very-high risk G3aA3, G3bA2-3, all G4, and all
G5 (Figure 1) [1]. Changes in the composite ranking be-
fore and six months after CCB treatment were assessed




High Very high and nephrotic
0 10-29 30-299 300-1999 ≥2000
albuminuria (KDIGO 2009).
Abe et al. BMC Nephrology 2013, 14:135 Page 4 of 10
http://www.biomedcentral.com/1471-2369/14/135was defined as an improved risk category after
amlodipine or benidipine treatment. On the other hand,
“Risk increase” was defined as a worsened risk category
after treatment.
Statistical analysis
Data were analyzed on the basis of randomly assigned
groups, regardless of participants’ subsequent medication
(intention-to-treat analysis), and expressed as the mean ±
SEM. Baseline characteristics of the patients were com-
pared between treatment groups using the unpaired t-test
and chi-squared test. Mean values of each group were
then compared using the unpaired t-test. The Stu-
dent’s t-test was applied to determine the effect of
treatment on BP, heart rate, and urinary albumin/Cr
ratio. eGFR time course data within group swere analyzed
by repeated-measures analysis of variance (ANOVA),
while changes between the two groups were analyzed by
two-way ANOVA followed by Dunnett’s test. Correlations
were determined using the Spearman rank correlation
test. Changes in risk categories were calculated according
to the following score allocation: No CKD, 0 points; mod-
erate risk, 1 point; high risk, 2 points; and very-high risk,
3 points, then changes in scores compared between base-




Age (years) 67.5 ± 1.5
Diabetes Mellitus (n(%)) 23(44.2)




Hemoglobin A1c (%) (for diabetes) 6.48 ± 0.15
Systolic blood pressure (mmHg) 145 ± 1.0
Diastolic blood pressure (mmHg) 81 ± 1.3
Sodium (mEq/L) 140 ± 0.3
Potassium (mEq/L) 4.4 ± 0.1
Baseline therapy (n(%))
Details of ARB
Telmisartan 80 mg daily 28(53.8)





CKD Chronic kidney disease, ACE angiotensin-converting enzyme, ARB, angiotensintest. Changes in the proportion showing a “Risk reduc-
tion” and “Risk increase” between groups were compared
using the chi-squared test. Statistical analyses were
performed with SPSS Version 19.0 (SPSS Inc., IL, USA)
with significance set at P < 0.05.Results
Study population and baseline characteristics
A total of 104 subjects were enrolled in this study and
randomly allocated to the benidipine (n = 52) or
amlodipine group (n = 52). Baseline characteristics and
medications at baseline are shown in Table 1. No signifi-
cant differences were observed between groups with re-
gard to baseline characteristics or the number of
patients with diabetic nephropathy. Adequate BP con-
trol had not been achieved at baseline in any of the en-
rolled patients. During treatment, two subjects from
each group were excluded because additional antihyper-
tensive medications (benidipine group: furosemide,
n = 1, thiazide diuretics, n = 1; amlodipine group: fur-
osemide, n = 2) were required to achieve the target BP
or improve edema. Therefore, 100 subjects completed
the trial. There was no significant difference in the pro-
portion of risk categories between groups at baseline.Benidipine group P value
(n = 52)
30/22 -





6.43 ± 0.11 0.93
144 ± 0.9 0.46
82 ± 1.4 0.73
140 ± 0.4 0.97







receptor blocker, Mean ± SEM using the unpaired t-test or chi-squared test.
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The final doses of benidipine and amlodipine for the
two groups were 6.3 ± 0.3 and 5.4 ± 0.4 mg per day, re-
spectively. Systolic and diastolic BPs were significantly
decreased in both groups by the end of the study com-
pared with baseline (both P < 0.001). Systolic BP was de-
creased by −17.1 ± 0.9 mmHg and −16.3 ± 0.8 mmHg in
the amlodipine and benidipine groups, respectively, but
the difference was not significant. Diastolic BP was also
decreased by − 9.1 ± 1.1 mmHg and −7.8 ± 0.9 mmHg,
respectively, but again the difference was not significant.
Heart rate at the end of the study was significantly re-
duced in the benidipine group compared with baseline
(benidipine group: 75.1 ± 1.4 to 73.7 ± 1.3 beats per min,
P < 0.001; amlodipine group: 74.5 ± 1.7 to 74.8 ± 1.6 beats
per min, not significant). A significant difference was
also observed in the change in heart rate between groups
(amlodipine group:+0.3 ± 0.6 beats per min; benidipine
group: −1.4 ± 0.4 beats per min; P =0.038).
Renoprotective effects
As shown in Table 2, there was a significant reduction in
the urinary albumin/Cr ratio in the benidipine group
(baseline 175.5 ± 22.4 mg/g·Cr to end of the study 120.6 ±
13.6 mg/g·Cr; P < 0.001), but not the amlodipine group
(baseline 173.2 ± 18.7 mg/g·Cr to the end 194.1 ±
34.6 mg/g·Cr). Figure 2 shows the changes in eGFR
during the 6-month treatment period in both groups.
Changes in eGFR were significantly decreased in the
amlodipine group (44.7 ± 1.7 mL/min/1.73 m2 at base-
line to 42.7 ± 1.9 mL/min/1.73 m2 at the end of the
study; P = 0.006), but no significant changes were ob-
served in the benidipine group (44.6 ± 1.9 mL/min/
1.73 m2 at baseline to 44.3 ± 2.1 mL/min/1.73 m2 at
the end of the study; P = 0.519). As shown in Table 2,Table 2 Changes in the urinary albumin/Cr ratio and eGFR
Amlodipine group
(n = 50)
Urinary albumin (mg/g • Cr)
Pre 173.2 ± 18.7
Post 194.1 ± 34.6
⊿Urinary albumin 20.8 ± 32.1
P value (pre vs. post) 0.774
eGFR (mL/min/1.73 m2)
Pre 44.7 ± 1.7
Post 42.7 ± 1.9
⊿eGFR −2.0 ± 0.7
P value (pre vs. post) 0.006
Mean ± SEM using the paired t-test or unpaired t-test.during the study period eGFR reduced by − 2.0 ± 0.7 mL/
min/1.73 m2 and −0.2 ± 0.7 mL/min/1.73 m2 in the
amlodipine and benidipine groups, respectively (P = 0.032).
There was no significant correlation between the changes
in albuminuria and eGFR in either group (amlodipine
group; r = 0.081, P = 0.575, benidipine group; r = −0.127,
P = 0.379).
Composite ranking of relative risk
Changes in risk categories in each group are shown in
Figure 3. Although there was no significant change in
the proportion of each category or relative risk scores
after amlodipine treatment, benidipine treatment signifi-
cantly decreased relative risk scores (P = 0.008). Further-
more, the proportion of those in the very high risk
category was significantly decreased after benidipine
treatment. Figure 4 shows the change in each category
between baseline and the end of treatment in both
groups. As shown in Figure 4B, the number of patients
in the G3bA2 category was significantly reduced by
benidipine treatment, although there were no changes in
any category in the amlodipine group (Figure 4A). As
shown in Figure 5A, a significant difference was noted
in the change in risk scores between the amlodipine and
benidipine groups. Furthermore, although there was no
significant difference in the proportion of unchanged
categories, the proportion showing “Risk reduction” was
significantly higher while that of “Risk increase” was sig-
nificantly lower in the benidipine group compared to the
amlodipine group. As shown in Figure 5B, “Risk reduc-
tion” was found in 5 (10%) and 10 cases (20%) in the
amlodipine and benidipine groups, respectively (P =
0.043). Moreover, although “Risk increase” was observed
in 7 cases (14%) in the amlodipine group, only 1 case
(2%) was found in the benidipine group (P = 0.027).Benidipine group P value
(n = 50) (Amlodipine
vs. Benidipine)
175.5 ± 22.4 0.965
120.6 ± 13.6 0.564
−54.9 ± 13.7 0.08
<0.001
44.6 ± 1.9 0.937
44.3 ± 2.1 0.051




















Amlodipine group (n = 50) 
Benidipinegroup (n = 50) 
1 2 3 4 5 6
Figure 2 Changes in estimated glomerular filtration rate
between the two treatment groups during the study period.
Grey circles: amlodipine group, black circles: benidipine group,
mean ± SEM.
Abe et al. BMC Nephrology 2013, 14:135 Page 6 of 10
http://www.biomedcentral.com/1471-2369/14/135Discussion
Recent studies have revealed that proteinuria and albu-
minuria are risk factors for both end-stage renal disease
and cardiovascular disease (CVD) in CKD patients
[2,17]. Accordingly, reductions in proteinuria and albu-
minuria are associated with a reducing trend in renal
death and cardiovascular events [18,19]. These findings
extend the novel concept that high albuminuria/protein-
uria alone should be a target for reducing hard end-
points, as in established treatments for high BP, high
blood glucose, and high LDL-cholesterol. Thus, albu-
minuria/proteinuria reduction is one of the most
important surrogate goals of hypertension treatment as
it reduces both renal death and CVD. It has also been
reported in post-hoc analysis of RENAAL and IDNT56 (28) 60 (30)
32 (16) 28 (14)











Figure 3 Changes in CKD severity according to KDIGO 2009 categorie
treatment groups. Numbers in bars indicate % (n). * P < 0.05 vs. at baselintrials that a dual approach targeting both BP and albu-
minuria is important in improving cardiovascular out-
comes [20]. Furthermore, post-hoc analysis of the IDNT
trial using eGFR as the principal outcome measure con-
firmed that ARB irbesartan significantly slows the long-
term rate of decline in eGFR, resulting in delayed pro-
gression towards ESRD by at least 33%. This finding
was explained by reductions in BP and proteinuria
[21]. Previous studies have demonstrated that the redu-
cing effects of benidipine on albuminuria/proteinuria are
due to efferent arteriolar dilation followed by attenuation
of glomerular hypertension [14,15,22,23]. In the present
study, the respective add-on effects of benidipine and
amlodipine on albuminuria reduction were demonstrated
in 100 CKD patients on top of the ARBs telmisartan and
olmesartan. Compared with amlodipine, albuminuria re-
duction was obtained with benidipine combined with
ARB. Moreover, benidipine reduced albuminuria while
maintaining the eGFR, and as a result, more patients
showed a “Risk reduction” after benidipine compared to
amlodipine treatment.
Meta-analysis of the effects of CCB on major adverse
cardiovascular events (MACE) in vasospastic angina pa-
tients revealed that the hazard ratio for the occurrence
of MACE was significantly lower in those treated with
benidipine than other CCBs [24,25]. Moreover, benidipine
is reportedly more selective towards coronary artery
smooth muscle cells that other CCBs amlodipine, nifedi-
pine, and diltiazem [26,27]. This higher selectivity of
benidipine towards coronary arteries might be due not only
to its inhibitory effect on coronary artery spasm, but also its

















































































































Figure 4 Changes in details of the KDIGO 2009 categories at baseline and after CCB treatment. In (A) the amlodipine group and (B) the
benidipine group. * P < 0.001 vs. at baseline.
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lasting effects, independent of the blood concentration
[28,29]. The beneficial prognostic effect of benidipine
compared with other CCBs was therefore noted, sug-
gesting involvement of vasculoprotective effects, but not
anti-vasospastic effects. Indeed, it was recently shown that
benidipine improves vascular endothelial function, includ-
ing flow-mediated dilation, pulse wave velocity, and the
augmentation index in patients with hypertension [30-32].
Moreover, benidipine was also shown to reduce myocar-
dial infarction (MI) size by increasing nitric oxide produc-
tion and inhibiting free radical production in a rabbit
model of MI [33].The mechanisms behind the association between albu-
minuria and CVD remain largely unknown and are the
focus of intensive research and debate [34,35]. It has
been suggested that albuminuria not only reflects glom-
erular damage, but also serves as a sensitive indicator of
generalized endothelial dysfunction and capillary vasculo-
pathy that leads to penetration of atherosclerotic lipopro-
teins into the arterial wall [36-38]. Studies have shown
that albuminuria is associated with endothelial dysfunction
in the systemic circulation [29]. As endothelial and vascu-
lar damage become advanced, more and more glomeruli
are injured, resulting in a substantial amount of albumin-












































Figure 5 Difference in CKD severity changes between the two treatment groups. (A) Changes in risk scores in the two treatment groups.
Numbers in bars indicate the number of patients. (B) Comparison of the proportion with “Risk reduction” and “Risk increase” between the two
treatment groups.
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systemic vascular lesions, is a very high risk factor for both
renal and cardiovascular events in subjects with CKD [35].
Thus, this suggests that the reduction in albuminuria by
benidipine is due not only to the efferent arteriolar dila-
tion effect but also the improvement in endothelial dys-
function. Since benidipine has vasculoprotective effects
on both the coronary artery and the glomerulus through
improvements in vascular endothelial function, it is
expected to reduce both renal events and cardiovascular
disease. However, determining whether this is indeed
the case based on the reduced risk category according
to the new KDIGO classification requires further long-
term investigations.
Although the risk categories in the KDIGO guidelines
were formed using pooled outcome data from multiple
populations through application of the Modification of
Diet in Renal Disease (MDRD) Study equation, it has
been reported that the Chronic Kidney Disease Epidemi-
ology Collaboration (CKD-EPI) equation more accur-
ately estimates GFR using the same variables, especially
at higher GFR [39]. The CKD-EPI equation is a better
predictor of risk than the MDRD Study equation in
CKD cohorts as well as in cohorts with higher eGFR
[39]. However, CKD-EPI equations were developed in
mostly Caucasian and African American populations. A
previous study revealed that eGFR values obtained using
CKD-EPI equations with sCr were significantly higherthan the actual GFR in Japanese subjects [40]. When the
eGFR was calculated using a coefficient-modified CKD-
EPI equation based on sCr (0.813 × CKD-EPI) in the
present study [41,42], changes in eGFR were 43.6 ±
2.6 mL/min/1.73 m2 at baseline to 41.2 ± 2.6 mL/min/
1.73 m2 at the end of the study (P = 0.006) in the
amlodipine group and 44.0 ± 2.8 mL/min/1.73 m2 at base-
line to 43.9 ± 3.3 mL/min/1.73 m2 at the end of the study
(P = 0.945) in the benidipine group. No significant differ-
ences were noted between the Japanese GFR equation and
the CKD-EPI equation when calculating the proportion of
each category or relative risk score. Therefore, we could
also use the CKD-EPI equation to assess the composite
ranking of relative risk on the basis of GFR values. When
the bias, precision, and accuracy of the GFR equations
were compared in Japanese subjects stratified by measured
GFR, Japanese GFR equations were revealed to be effect-
ive for patients with a GFR < 60 mL/min/1.73 m2, com-
pared with the coefficient-modified CKD-EPI equations
[40]. Furthermore, in a study using the Japanese GFR
equation, reduced eGFR was independently associated
with incident CVD events in Japanese patients with type-2
diabetic nephropathy and patients with non-diabetic CKD
[43,44]. In the present study, since the mean eGFR at
baseline was 44.6 ± 1.9 mL/min/1.73 m2, we assessed the
changes in eGFR using the Japanese GFR equation.
Despite the present findings, our study is limited by
the relatively small sample size and the short period of
Abe et al. BMC Nephrology 2013, 14:135 Page 9 of 10
http://www.biomedcentral.com/1471-2369/14/135treatment. Moreover, the changes in sCr levels were too
small for adequate evaluation of the influence of CCB
therapy. It has been reported that there is insufficient
evidence to assume that a reduction in albuminuria
levels will lead to an improvement in clinical outcomes
such as progression to ESRD, a CVD event, or death
[45]. Additional studies are therefore necessary to more
firmly establish the validity of changes in albuminuria as
a surrogate for kidney disease progression. Further-
more, long-term investigations are also necessary to
accurately assess the preventive renal and cardiovas-
cular effects of benidipine therapy in patients with
CKD. Moreover, to assess the changes in risk categor-
ies of the KDIGO classification that precisely reflect
prognosis, requirements for renal replacement therapy
and other renal or cardiovascular events should be
considered endpoints.
Conclusions
The present post-hoc analysis showed that compared to
amlodipine, an L-type CCB, benidipine, an L- and T-
type CCB, results in a greater reduction in albuminuria
and improved composite ranking of relative risk
according to the 2009 KDIGO CKD severity classifica-
tion in patients with CKD. These effects of benidipine
seem to make the drug more advantageous in terms of
the progression of renal outcome and prevention of car-
diovascular events in patients with hypertensive CKD.
However, further studies are needed to determine
whether long-term use of benidipine can actually reduce
renal events and cardiovascular morbidity in patients
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